Drugs / Autologous Multi-lineage Potential Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03825146 | Jan 2019 → Jan 2021 | acute myeloid leukemia | Lai Corporation Pty. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Multi-lineage Potential Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03825146 ↗ |
| Known as | AMPC | “Autologous Multi-lineage Potential Cells (AMPC)” NCT03825146 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT03825146 ↗ |